Key result
H. pylori-negative patients with a history of aspirin or antiplatelet agent use had the highest risk of peptic ulcer bleeding (OR 3.03; 95% CI 1.48-6.18).
Why the study?
What are the risk factors, including H. pylori and antiplatelet agents, for peptic ulcer bleeding in patients with peptic ulcer disease?
Population
475 patients with peptic ulcer disease (265 with bleeding PUD and 210 with non-bleeding PUD)
Comparison
Exposure to NSAIDs, aspirin, and antiplatelet… vs Non-bleeding peptic ulcer disease / absence of…
Design
Case-control
Authors
Loading...
Antiplatelet-associated bleeding risk appears highest when H. pylori-negative; hypothesis-generating interaction requires prospective confirmation before practice implications.
Case-Control (n=475)
What are the risk factors, including H. pylori and antiplatelet agents, for peptic ulcer bleeding in patients with peptic ulcer disease?
Odds Ratio: 3.03 (95% CI 1.48–6.18)
Aspirin and antiplatelet use significantly increases the risk of peptic ulcer bleeding, with the highest risk observed in H. pylori-negative patients.
Kang et al. (2011) conducted a case-control in Peptic ulcer disease (n=475). Aspirin or antiplatelet agent use in H. pylori-negative patients vs. H. pylori-positive patients with no history of aspirin/antiplatelet agent use was evaluated on Peptic ulcer bleeding (OR 3.03, 95% CI 1.48-6.18). H. pylori-negative patients with a history of aspirin or antiplatelet agent use had the highest risk of peptic ulcer bleeding (OR 3.03; 95% CI 1.48-6.18).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: